A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1: To assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine. Phase 2: To assess preliminary efficacy as determined by overall response rate (ORR).
University of Colorado Hospital
Brad Haverkos, MD
Protocol Number: 22-1202
More information available at ClinicalTrials.gov: NCT05403450
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers